Julien Torgue

979 total citations
33 papers, 790 citations indexed

About

Julien Torgue is a scholar working on Radiology, Nuclear Medicine and Imaging, Epidemiology and Oncology. According to data from OpenAlex, Julien Torgue has authored 33 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Radiology, Nuclear Medicine and Imaging, 15 papers in Epidemiology and 14 papers in Oncology. Recurrent topics in Julien Torgue's work include Radiopharmaceutical Chemistry and Applications (23 papers), Neuroendocrine Tumor Research Advances (15 papers) and Neuroblastoma Research and Treatments (8 papers). Julien Torgue is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (23 papers), Neuroendocrine Tumor Research Advances (15 papers) and Neuroblastoma Research and Treatments (8 papers). Julien Torgue collaborates with scholars based in United States, France and Germany. Julien Torgue's co-authors include Julia E. Grimwade, Alan C. Leonard, Patty Bunch, Ruby F. Meredith, Christian J. Nievera, Sui Shen, J. Michael Straughn, Ronald D. Alvarez, Tania A. Rozgaja and Ebrahim S. Delpassand and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Julien Torgue

33 papers receiving 783 citations

Peers

Countries citing papers authored by Julien Torgue

Since Specialization

Citations

This map shows the geographic impact of Julien Torgue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Torgue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Torgue more than expected).

Fields of papers citing papers by Julien Torgue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Torgue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Torgue. The network helps show where Julien Torgue may publish in the future.

Co-authorship network of co-authors of Julien Torgue

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Torgue. A scholar is included among the top collaborators of Julien Torgue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Torgue. Julien Torgue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Side-by-Side Comparison of the In Vivo Performance of [²¹²Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds 2025 ·Journal of Nuclear Medicine ·(unknown), (unknown), Amy G. Wong, (unknown), (unknown), Julien Torgue	2
2	Safety, tolerability and efficacy of ²¹²Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study. 2024 ·Journal of Clinical Oncology ·Jonathan Strosberg, (unknown), Allen Lee Cohn, Ebrahim S. Delpassand, Volker Jean Wagner, Izabela Tworowska, Julien Torgue, (unknown), Allison M. Manuel, Mary A. Maluccio	12
3	Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model 2024 ·Journal of Nuclear Medicine ·(unknown), (unknown), (unknown), Julien Torgue	6
4	Bone Marrow Relative Biological Effectiveness for a 212Pb-labeled Anti-HER2/neu Antibody 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Ioanna Liatsou, Anders Josefsson, Jing Yu, (unknown), Remco Bastiaannet, Esteban Velarde, (unknown), Cory Brayton, Hao Wang, Julien Torgue, Robert F. Hobbs, George Sgouros	3
5	Abstract 5432: Targeted alpha therapy with 212Pb-NNV003 in treatment of NHL 2022 ·Cancer Research ·Jostein Dahle, (unknown), (unknown), Helèn Heyerdahl, (unknown), Julien Torgue	1
6	²¹²Pb-conjugated anti-rat HER2/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro 2022 ·International Journal of Radiation Biology ·Ioanna Liatsou, Jing Yu, Remco Bastiaannet, Zhi Li, Robert F. Hobbs, Julien Torgue, George Sgouros	5
7	Mathematical Modeling of In Vivo Alpha Particle Generators and Chelator Stability 2021 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Peter Kletting, Ambros J. Beer, (unknown), Julien Torgue, Gerhard Glatting	5
8	Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma 2021 ·British Journal of Cancer ·(unknown), Jacques Monteil, (unknown), (unknown), Marie‐Annick Clavel, (unknown), Julien Torgue, Michel Cogné, Isabelle Quelven	19
9	Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003 2020 ·PLoS ONE ·(unknown), (unknown), Julien Torgue, Helèn Heyerdahl, (unknown), Arne Kolstad, Jostein Dahle	29
10	First-in-Human dose escalation of AlphaMedixTM for Targeted Alpha-Emitter Therapy of NETs 2020 ·Ebrahim S. Delpassand, Izabela Tworowska, Julien Torgue, (unknown), (unknown), David Ranganathan, Rodolfo Núñez	3
11	Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model 2019 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Izabela Tworowska, Ebrahim S. Delpassand, Julien Torgue	59
12	Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy 2019 ·Clinical Cancer Research ·(unknown), Catherine Lozza, Alexandre Pichard, Julie Constanzo, (unknown), (unknown), Emmanuel Deshayes, Vincent Boudousq, Salomé Paillas, Muriel Busson, (unknown), Marta Jarlier, S Marcatili, Manuel Bardiès, Frank Bruchertseifer, Aliyah Morgenstern, Julien Torgue, Isabelle Navarro‐Teulon, Jean‐Pierre Pouget	31
13	Theranostic 203/212Pb-labeled octreotate analogs (AlphaMedix TM) and their preclinical characterization for the Phase I clinical studies in neuroendocrine cancer patients 2019 ·Nuclear Medicine and Biology ·Izabela Tworowska, (unknown), Ebrahim S. Delpassand, Julien Torgue, (unknown), Paul Jurek, (unknown), (unknown), (unknown), Eric C. Frey, George Sgouros	1
14	Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL) 2018 ·Blood ·(unknown), (unknown), Julien Torgue, Helèn Heyerdahl, Jostein Dahle	3
15	Abstract LB-259: Pb203-AR-RMX conjugates for image-guided TAT of neuroendocrine tumors (NETs) 2017 ·Cancer Research ·Izabela Tworowska, (unknown), (unknown), (unknown), (unknown), Paul Jurek, Garry E. Kiefer, Julien Torgue, Ebrahim S. Delpassand	4
16	Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with ²¹²Pb-TCMC-Trastuzumab 2014 ·Journal of Nuclear Medicine ·Ruby F. Meredith, Julien Torgue, Sui Shen, Darrell R. Fisher, (unknown), Patty Bunch, Desiree E. Morgan, Jinda Fan, J. Michael Straughn	104
17	Pharmacokinetics and Imaging of ²¹² Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients 2013 ·Cancer Biotherapy and Radiopharmaceuticals ·Ruby F. Meredith, Julien Torgue, Michael Azure, Sui Shen, Souheil Saddekni, (unknown), (unknown), Patty Bunch, Daniel Yoder, Ronald D. Alvarez	107
18	Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb 2013 ·PLoS ONE ·Vincent Boudousq, Laure Bobyk, Muriel Busson, Véronique Garambois, Marta Jarlier, (unknown), André Pèlegrin, Salomé Paillas, Nicolas Chouin, François Quénet, (unknown), Julien Torgue, Isabelle Navarro‐Teulon, Jean‐Pierre Pouget	55
19	Mutational analysis reveals Escherichia coli oriC interacts with both DnaA‐ATP and DnaA‐ADP during pre‐RC assembly 2007 ·Molecular Microbiology ·Julia E. Grimwade, Julien Torgue, (unknown), (unknown), (unknown), Alan C. Leonard	36
20	SeqA Blocking of DnaA-oriC Interactions Ensures Staged Assembly of the E. coli Pre-RC 2006 ·Molecular Cell ·Christian J. Nievera, Julien Torgue, Julia E. Grimwade, Alan C. Leonard	101

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact